This comprehensive review highlights the role of circulating tumor cells and detection technologies in urological cancers, suggesting potential clinical applications.
Circulating tumor cells (CTCs) are the rare cells that detach from primary or metastatic tumors and circulate in the bloodstream. Their role as a liquid biopsy tool has garnered increasing attention, particularly in urological cancers, which include prostate, bladder, kidney, and testicular cancers. This review discusses the biology, detection technologies, clinical applications, and current challenges of CTCs in urological malignancies, with a special emphasis on their prognostic and predictive utility.
No takes yet. Share an insight, caveat, or question.
Nivedita Suresh (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: